Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Par Pharmaceutical, Inc.

Home Clinical Trial Sponsors and OrganizationsPar Pharmaceutical, Inc.

Par Pharmaceutical, Inc.

300 Tice Blvd Ste 230, Woodcliff Lake, New Jersey, United States

Also known as:

par pharmaceuticals, inc.

par pharmaceutial inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

38

2 active

Approvals

290

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

31

81.6%

Phase 3

5

13.2%

Phase 2

1

2.6%

Trial Status Distribution

Active, not recruiting

2

5.3%

Completed

31

81.6%

Terminated

5

13.2%

Clinical Trials

Trials sponsored by this organization (38)

Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

Jun 2016582 participants

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Nov 2013203 participants

A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa

Jul 2013455 participants

A MULTI-NATIONAL, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY TO COMPARE THE SAFETY AND EFFICACY OF 200 mg PAR-101 TAKEN q12h WITH 125 mg VANCOMYCIN TAKEN q6h FOR TEN DAYS IN SUBJECTS WITH CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA

Active, not recruiting

Mar 2007664 participants

ESTUDIO MULTINACIONAL, MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO Y DE GRUPOS PARALELOS PARA COMPARAR LA SEGURIDAD Y LA EFICACIA DE 200 mg DE PAR-101 CADA 12 HORAS CON 125 mg DE VANCOMICINA CADA 6 HORAS DURANTE DIEZ DÍAS EN SUJETOS CON DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILEA multi-national, multi-centre, double-blind, randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects with Clostridium Difficile-associated diarrhea - A double-blind, randomised study of PAR-101 vs vancomycin in CDAD

Active, not recruiting

Mar 2007664 participants

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Jun 20065 participants

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Jun 20064 participants

Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension

May 20067 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

290

Approvals

Recent Approvals

Propranolol Hydrochloride

Propranolol Hydrochloride

Fluphenazine Decanoate

Fluphenazine Decanoate

Doxylamine Succinate and Pyridoxine Hydrochloride

Doxylamine Succinate and Pyridoxine Hydrochloride

News

No news articles found

On this page

Overview
Clinical Trials38
Approvals290
News

Back to Organizations